NO20090887L - Fremgangsmate for behandling og forebygging av mukositt - Google Patents

Fremgangsmate for behandling og forebygging av mukositt

Info

Publication number
NO20090887L
NO20090887L NO20090887A NO20090887A NO20090887L NO 20090887 L NO20090887 L NO 20090887L NO 20090887 A NO20090887 A NO 20090887A NO 20090887 A NO20090887 A NO 20090887A NO 20090887 L NO20090887 L NO 20090887L
Authority
NO
Norway
Prior art keywords
treating
mucositis
proantocyanidin
effective amount
therapeutically effective
Prior art date
Application number
NO20090887A
Other languages
English (en)
Other versions
NO341742B1 (no
Inventor
Paolo Morazzoni
Ezio Bombardelli
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37309334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090887(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indena Spa filed Critical Indena Spa
Publication of NO20090887L publication Critical patent/NO20090887L/no
Publication of NO341742B1 publication Critical patent/NO341742B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Fremgangsmåter for å behandle og forebygge mukositt, spesielt mukositt som følger administrasjonen av kjemoterapimedikamenter eller en kombinasjon av nevnte medikamenter med radioterapi er beskrevet heri. Mer spesielt er det beskrevet heri administrasjonen av en terapeutisk effektiv mengde av minst et av et antocyanosid, et proantocyanidin eller et ekstrakt inneholdende minst et av et antocyanosid eller et proantocyanidin for behandling eller forebygging av mukositt. Den terapeutisk effektive mengde av antocyanosidet, proantocyanidinet eller ekstraktet kan bli administrert alene eller i kombinasjon med en terapeutisk effektiv mengde av minst et av et anti-inflammatorisk middel, immunomodulerende middel, bedøvelsesmiddel, antimikrobielt middel eller antifungalt middel. Det er også beskrevet heri farmasøytiske sammensetninger til behandling eller forebygging av mukositt.
NO20090887A 2006-07-28 2009-02-26 Farmasøytisk sammensetning for anvendelse ved forebygging eller behandling av mukositt NO341742B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06015732A EP1882473A1 (en) 2006-07-28 2006-07-28 Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs
PCT/IB2007/002147 WO2008012666A2 (en) 2006-07-28 2007-07-27 Treatment and prevention mucositis by anthocyanidin derivatives

Publications (2)

Publication Number Publication Date
NO20090887L true NO20090887L (no) 2009-02-26
NO341742B1 NO341742B1 (no) 2018-01-15

Family

ID=37309334

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090887A NO341742B1 (no) 2006-07-28 2009-02-26 Farmasøytisk sammensetning for anvendelse ved forebygging eller behandling av mukositt

Country Status (20)

Country Link
US (3) US20080026058A1 (no)
EP (4) EP1882473A1 (no)
JP (1) JP5433415B2 (no)
KR (1) KR20090052852A (no)
CN (1) CN101495114A (no)
AU (1) AU2007278959B2 (no)
BR (1) BRPI0715364A2 (no)
CA (2) CA2659211C (no)
DK (2) DK2520295T3 (no)
ES (2) ES2602786T3 (no)
HU (2) HUE031941T2 (no)
IL (1) IL196737A (no)
MX (1) MX2009001064A (no)
NO (1) NO341742B1 (no)
PL (2) PL2046324T3 (no)
PT (2) PT2046324T (no)
RU (1) RU2438693C2 (no)
SG (1) SG172745A1 (no)
SI (2) SI2046324T1 (no)
WO (1) WO2008012666A2 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20042414A1 (it) * 2004-12-17 2005-03-17 Indena Spa Formulazione per il trattamento di affezioni delle prime vie respiratorie
ITMI20080038A1 (it) * 2008-01-11 2009-07-12 Indena Spa Formulazioni per il trattamento di mucositi indotte da terapia antitumorale o immunosoppressiva
ITMI20080395A1 (it) * 2008-03-10 2009-09-11 Indena Spa Formulazioni per il trattamento delle verruche e delle placche psoriatiche
AU2009240294B2 (en) * 2008-04-24 2014-04-10 Indena S.P.A. Compositions for the treatment and prevention of infections of the oral cavity
CN102014906A (zh) * 2008-04-24 2011-04-13 因德纳有限公司 治疗具有慢性炎症的阴道感染的组合物
ATE526968T1 (de) * 2008-06-12 2011-10-15 Indena Spa Zusammensetzungen zur behandlung von vaginalen infektionen mit chronischer entzündung
ES2334746B1 (es) * 2008-07-23 2011-01-28 Feedback Trayer, S.L. Producto para la higiene intima a base de mirtillo rojo y procedimiento para su preparacion.
JP2010215532A (ja) * 2009-03-13 2010-09-30 Ands Corporation コラーゲンゲル収縮促進剤
EP2344154B1 (en) * 2009-10-21 2016-12-07 Maqui New Life S.A. Compositions that include anthocyanidins and methods of use
IT1402749B1 (it) * 2010-10-28 2013-09-18 Indena Spa Composizioni per il trattamento di ulcere periferiche di varia origine
FR2979241B1 (fr) 2011-08-30 2014-05-09 Nutrialys Medical Nutrition Sa Utilisation de compositions a faible teneur en polyamines dans la prevention ou le traitement des effets indesirables lies a un traitement anti-cancereux
ITMI20111671A1 (it) * 2011-09-16 2013-03-17 Indena Spa Composizioni per il trattamento di ulcere periferiche di varia origine
CN104145966B (zh) * 2014-07-23 2016-09-07 中国人民解放军第二军医大学 白屈菜红碱在制备抗真菌生物被膜药物中的应用
JP6700083B2 (ja) * 2016-03-30 2020-05-27 株式会社ファンケル 口腔内速崩壊錠
JP6700084B2 (ja) * 2016-03-30 2020-05-27 株式会社ファンケル コーティング顆粒
CN106361755A (zh) * 2016-10-23 2017-02-01 徐州诺克非医药科技有限公司 含Zoarenone用于治疗溃疡性结肠炎的药物
KR20190079641A (ko) * 2016-10-27 2019-07-05 엔에스이 프로덕츠, 인크. 장 건강 촉진 조성물
CN108721276B (zh) * 2018-06-29 2020-01-07 佛山科学技术学院 一种小白菊内酯和原花青素复方药物组合物及其用途
CN109549946B (zh) * 2019-01-08 2020-12-18 牡丹江医学院 一种治疗咽炎的药物及其制备方法
CN117298094A (zh) * 2023-09-27 2023-12-29 青海瑞成药业(集团)有限公司 氯化矢车菊素协同氟康唑在制备抗耐药真菌的药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145412A (en) 1977-02-14 1979-03-20 Vipont Chemical Company Composition for application to oral cavity and method for preparation thereof
GB2062991B (en) * 1979-11-07 1983-11-16 Image Data Products Ltd Position co-ordinates digitiser
US4818533A (en) 1985-07-09 1989-04-04 Vipont Pharmaceutical, Inc. Production of high purity alkaloids
IT1231725B (it) * 1989-08-11 1991-12-21 Inverni Della Beffa Spa Procedimento per la preparazione di estratti ad alto contenuto in antocianosidi.
DK0464298T3 (da) 1990-07-05 1995-11-13 Indena Spa Echinacea-ekstrakter, fremgangsmåde til fremstilling deraf og formuleringer, der indeholder dem
JP2754906B2 (ja) * 1990-11-06 1998-05-20 日本電気株式会社 半導体集積回路
US5073368A (en) * 1991-05-15 1991-12-17 Colgate-Palmolive Company Sanguinaria mouthrinse having improved anti microbial activity and stability
US5378465A (en) 1993-05-24 1995-01-03 Zeines; Victor Solution for application to an oral cavity
IT1270999B (it) * 1994-07-26 1997-05-26 Indena Spa Formulazioni a base di cumarine e loro uso in campo farmaceutico e cosmetico
NO943860D0 (no) * 1994-10-13 1994-10-13 Unifob En kjemisk forbindelse og et preparat til bruk som terapeutikum
AU2578997A (en) * 1996-04-17 1997-11-19 Unifob Use of anthocyanidin and anthocyanidin derivatives
US5840322A (en) 1996-12-19 1998-11-24 Ramot-University Authority For Applied Research & Industrial Devel. Ltd. Anti-oral-microbial adhesion fraction derived from vaccinium
ITMI981542A1 (it) 1998-07-07 2000-01-07 Indena Spa Estratti di zanthoxylum bungeanum e loro formulazioni farmaceutiche e cosmetiche
US6162393A (en) 1998-08-06 2000-12-19 Ndt, Inc. Contact lens and ophthalmic solutions
JP2001039844A (ja) * 1999-07-29 2001-02-13 Kikkoman Corp 咽喉用うがい剤
KR20060123663A (ko) * 1999-08-27 2006-12-01 미시간 스테이트 유니버시티 천연 사이클로옥시게나제 저해물질을 함유하는 조성물
ITMI20000628A1 (it) * 2000-03-24 2001-09-24 Indena Spa Composizioni cosmetiche ritardanti la ricrescita dei peli
AT500455B1 (de) * 2000-09-15 2007-08-15 Roth Hermann Dr Verwendung von benzophenanthridinalkaloiden als futteradditiv
EP1236466B1 (en) * 2001-02-28 2011-09-21 Axiomedic Ltd. Solid self-adhesive compositions for topical treatment of oral mucosal disorders
WO2002092028A2 (en) 2001-05-15 2002-11-21 The Procter & Gamble Company Oral care compositions
IL143318A0 (en) * 2001-05-23 2002-04-21 Herbal Synthesis Corp Herbal compositions for the treatment of mucosal lesions
US6596313B2 (en) * 2001-08-06 2003-07-22 The Quigley Corporation Nutritional supplement and methods of using it
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
JP2005530738A (ja) * 2002-04-16 2005-10-13 アイシス・イノヴェイション・リミテッド 組織障害の予防及び／又は治療のためのクルクミン
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
GB0230042D0 (en) * 2002-12-23 2003-01-29 Britannia Pharmaceuticals Ltd Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation
FR2856304B1 (fr) * 2003-06-20 2006-03-03 Natural Product Consulting Composition pour la prevention des infections du systeme urinaire
ITMI20032287A1 (it) * 2003-11-24 2005-05-25 Indena Spa Composizioni per il trattamento delle affezioni del cavo orale e delle prime vie respiratorie
KR101531116B1 (ko) * 2004-04-28 2015-06-23 누트리션 사이언스 파트너스 리미티드 천심련으로부터의 조추출물
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
ITMI20042414A1 (it) 2004-12-17 2005-03-17 Indena Spa Formulazione per il trattamento di affezioni delle prime vie respiratorie
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
CA2622286A1 (en) * 2005-09-27 2007-04-05 University Of Kentucky Research Foundation Anti-inflammatory composition comprising berry extract

Also Published As

Publication number Publication date
DK2520295T3 (en) 2016-12-12
AU2007278959B2 (en) 2013-03-28
EP2520295B1 (en) 2016-08-17
HUE031034T2 (en) 2017-06-28
IL196737A (en) 2014-05-28
AU2007278959A1 (en) 2008-01-31
NO341742B1 (no) 2018-01-15
US20100310684A1 (en) 2010-12-09
ES2602786T3 (es) 2017-02-22
SG172745A1 (en) 2011-07-28
EP2046324A2 (en) 2009-04-15
JP5433415B2 (ja) 2014-03-05
SI2046324T1 (sl) 2017-06-30
IL196737A0 (en) 2009-11-18
US9730952B2 (en) 2017-08-15
DK2046324T3 (en) 2017-06-12
ES2629306T3 (es) 2017-08-08
JP2009544687A (ja) 2009-12-17
US20170304341A1 (en) 2017-10-26
CA2935902C (en) 2019-02-19
EP2522345A1 (en) 2012-11-14
BRPI0715364A2 (pt) 2013-06-18
PL2046324T3 (pl) 2017-09-29
EP2046324B1 (en) 2017-04-05
HUE031941T2 (en) 2017-08-28
MX2009001064A (es) 2009-02-05
KR20090052852A (ko) 2009-05-26
PT2520295T (pt) 2016-11-21
CA2659211A1 (en) 2008-01-31
RU2009102649A (ru) 2010-08-10
US20080026058A1 (en) 2008-01-31
PT2046324T (pt) 2017-07-03
CA2659211C (en) 2016-08-16
EP2520295A1 (en) 2012-11-07
SI2520295T1 (sl) 2016-11-30
CN101495114A (zh) 2009-07-29
CA2935902A1 (en) 2008-01-31
EP1882473A1 (en) 2008-01-30
WO2008012666A3 (en) 2008-09-04
RU2438693C2 (ru) 2012-01-10
WO2008012666A2 (en) 2008-01-31
PL2520295T3 (pl) 2017-02-28

Similar Documents

Publication Publication Date Title
NO20090887L (no) Fremgangsmate for behandling og forebygging av mukositt
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
NO20091191L (no) Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
BR112022014861A2 (pt) Métodos de tratamento para deficiência de alfa-1 antittripsina
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
EP4491187A4 (en) Pharmaceutical composition, adsorption method, treatment method, and prevention method
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
WO2006113718A3 (en) Compositions for the treatment of neoplasms
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
EA200801890A1 (ru) Средство для лечения шума в ушах
JP2011500650A5 (no)
WO2024006971A3 (en) Antimalarial compounds
NO20064753L (no) Kombinasjonsterapi

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees